Caption Management’s Vir Biotechnology VIR Stock Holding History

Caption Management’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-40,000	Closed	-$202K	–	2063
2025 Q2	$202K	Hold	40,000	–	–	﹤0.01%	1259
2025 Q1	$259K	Buy	+40,000	New	+$356K	﹤0.01%	1227
2024 Q4	–	Sell	-18,000	Closed	-$135K	–	1850
2024 Q3	$135K	Buy	+18,000	New	+$156K	﹤0.01%	1104
2024 Q2	–	Sell	-22,500	Closed	-$228K	–	1536
2024 Q1	$228K	Sell	22,500 -75,000	-77%	-$764K	﹤0.01%	992
2023 Q4	$981K	Buy	+97,500	New	+$891K	0.01%	811
2023 Q3	–	Sell	-100,000	Closed	-$2.45M	–	1565
2023 Q2	$2.45M	Buy	100,000 +85,000	+567%	+$2.13M	0.04%	445
2023 Q1	$349K	Buy	+15,000	New	+$384K	0.01%	858
2022 Q4	–	Sell	-30,000	Closed	-$578K	–	1752
2022 Q3	$578K	Buy	+30,000	New	+$763K	0.01%	1034
2022 Q1	–	Sell	-191,100	Closed	-$8M	–	1979
2021 Q4	$8M	Buy	+191,100	New	+$7.49M	0.09%	313
2021 Q2	–	Sell	-45,000	Closed	-$2.31M	–	1588
2021 Q1	$2.31M	Buy	+45,000	New	+$2.43M	0.05%	476

Other funds holding VIR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GSK plc London $599M AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Caption Management's VIR Position: Q3 2025 in Review

Caption Management sold out of Vir Biotechnology (VIR) in Q3 2025, closing a stake of 12,600 shares — an estimated $64.4K sold.

Caption Management first reported a position in VIR in Q1 2023 and held it in 4 quarters. The position peaked at $175K in Q1 2023. 213 funds tracked by Wall St. Rank hold VIR as of Q3 2025.

Caption Management reported no remaining Vir Biotechnology position as of Q3 2025 after selling out during the quarter.
Caption Management sold 12,600 Vir Biotechnology shares in Q3 2025, an estimated $64.4K.
Caption Management first reported a position in Vir Biotechnology in Q1 2023 and held it in 4 quarters.
Caption Management's Vir Biotechnology position peaked at $175K in Q1 2023.
213 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2025.

Based on Caption Management's 13F filing for Q3 2025, filed 14 Nov 2025.